KALA BIO (KALA) Stock Price, News & Analysis

Company Overview

KALA BIO, Inc., formerly known as Kala Pharmaceuticals, is a clinical-stage biotechnology company focused on developing treatments for severe diseases affecting the eye. The company’s research has centered on therapies designed to address conditions for which available treatment options may be limited or inadequate.

KALA BIO’s lead investigational product has been KPI-012, an ophthalmic biologic being studied for rare corneal conditions, including persistent corneal epithelial defects. The company has also developed therapies using its proprietary mucus-penetrating particle technology, which is intended to improve the delivery of medicines to ocular tissues.

Historically, the company developed and commercialized EYSUVIS, a corticosteroid eye drop approved in the United States for the short-term treatment of dry-eye disease, and XIPERE, an injectable treatment for macular edema associated with uveitis. KALA BIO is headquartered in the United States and has primarily focused its development and regulatory activities on the U.S. ophthalmology market.

Key Stats

• Today's Range: $0.18 to $0.20
• 50-Day Range: $0.19 to $0.95
• 52-Week Range: $0.11 to $95.50
• Volume: 286,699 shs
• Average Volume: 3.92 million shs
• Market Capitalization: $3.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

KALA BIO Stock Analysis - MarketRank™

KALA BIO scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

KALA BIO has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

KALA BIO has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KALA BIO has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.19% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 205.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KALA BIO does not currently pay a dividend.

Dividend Growth

KALA BIO does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.59

News Sentiment

KALA BIO has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for KALA BIO this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, KALA BIO insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.24% of the stock of KALA BIO is held by insiders.

Percentage Held by Institutions

24.61% of the stock of KALA BIO is held by institutions.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 10/16/2026
• AGM 2026: 11/03/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KALA
• CIK: 1479419
• Web: www.kalarx.com
• Phone: (781) 996-5252
• Fax: 781-642-0399
• Employees: 6
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($31.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -222.35%
• Return on Assets: -70.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.88
• Quick Ratio: 6.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.56 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 19,340,000
• Free Float: 18,907,000
• Market Cap: $3.67 million
• Optionable: Not Optionable
• Beta: -2.40